{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors+Chimeric+Antigen&page=7",
    "query": {
      "condition": "Receptors Chimeric Antigen",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 377,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors+Chimeric+Antigen&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors+Chimeric+Antigen&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T14:19:55.525Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06518668",
      "title": "A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "NKX019",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide LD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2024-07-01",
      "completion_date": "2040-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06518668"
    },
    {
      "nct_id": "NCT02159716",
      "title": "CART-meso in Mesothelin Expressing Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic (Ductal) Adenocarcinoma",
        "Epithelial Ovarian Cancer",
        "Malignant Epithelial Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "CART-meso",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2014-06",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159716"
    },
    {
      "nct_id": "NCT07735533",
      "title": "A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, B Cell",
        "Lymphoma Non-Hodgkin",
        "High Grade B Cell Lymphoma",
        "Richter Transformation Lymphoma",
        "Grade 3b Follicular Lymphoma",
        "Primary Mediastinal B Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "UB-VV400",
          "type": "GENETIC"
        },
        {
          "name": "Rapamycin (sirolimus)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Umoja Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2026-09",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07735533"
    },
    {
      "nct_id": "NCT06544330",
      "title": "A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Lupus Nephritis",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "SYNCAR-001",
          "type": "DRUG"
        },
        {
          "name": "STK-009",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synthekine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-04-29",
      "completion_date": "2041-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06544330"
    },
    {
      "nct_id": "NCT05474378",
      "title": "B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Nervous System"
      ],
      "interventions": [
        {
          "name": "B7-H3CART",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2022-07-12",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05474378"
    },
    {
      "nct_id": "NCT06895473",
      "title": "Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2025-06-04",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06895473"
    },
    {
      "nct_id": "NCT06090864",
      "title": "ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Relapse",
        "Refractory"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Cell infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2024-04-25",
      "completion_date": "2033-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06090864"
    },
    {
      "nct_id": "NCT03602157",
      "title": "Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Immune System Diseases",
        "Immunoproliferative Disorders",
        "Lymphatic Diseases",
        "Lymphoproliferative Disorders",
        "Neoplasms",
        "Cutaneous Lymphoma",
        "Cutaneous Anaplastic Large Cell Lymphoma",
        "Mycosis Fungoides",
        "Sezary Syndrome",
        "Lymphomatoid Papulosis",
        "Cutaneous T Cell Lymphoma",
        "Gray Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "ATLCAR.CD30.CCR4 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALTCAR.CD30 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2018-10-29",
      "completion_date": "2039-11-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602157"
    },
    {
      "nct_id": "NCT05621291",
      "title": "A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "B-All",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "NGS testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-10-14",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05621291"
    },
    {
      "nct_id": "NCT06786533",
      "title": "Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)"
      ],
      "interventions": [
        {
          "name": "Anti-FLT3 CAR-T cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hemogenyx Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2025-01-23",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-10T14:19:55.525Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06786533"
    }
  ]
}